This study is in progress, not accepting new patients
Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
Non Small Cell Lung Cancer (NSCLC) PD1 PD-1 PDL1 PD-L1 Lung Neoplasms Carcinoma, Non-Small-Cell Lung Docetaxel Pembrolizumab Pembrolizumab 2 mg/kg Pembrolizumab 10 mg/kg Docetaxel 75 mg/m^2
Lead Scientist at UCSF
- Matthew Gubens
Associate Professor, Medicine. Authored (or co-authored) 42 research publications.